Your session is about to expire
← Back to Search
Continuous Glucose Monitoring for Type 1 Diabetes
Study Summary
This trial is testing whether continuous glucose monitoring will improve blood sugar control in children and young adults with type 1 diabetes in East Africa.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am under 18 and have a parent or guardian to consent for me, or I am 18-26 and can consent for myself.I have been diagnosed with Type 1 Diabetes for at least a year.The patient already has a continuous glucose monitor (CGM).I am between 4 and 26 years old and live in Uganda.I am currently on insulin therapy.
- Group 1: SMBG levels 3x/daily (standard diabetes management)
- Group 2: Libre 2
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any opportunities to participate in this experiment currently available?
"Affirmative. Data found on clinicaltrials.gov verifies that this medical research is open for recruitment, with a start date of August 15th 2022 and an update made as recently as September 16th 2022. In total, 180 patients need to be recruited from one site only."
Is the minimum age requirement to participate in this experiment below thirty years old?
"The qualifications for this medical trial are that patients must be aged between 4 and 26 years old. There is a total of 217 studies available to those under 18 while 919 research opportunities exist for people over 65."
Is it possible to join this research project?
"This diabetes mellitus intervention is searching for 180 participants aged 4 to 26, who must meet the following requirements: reside in Uganda, have a diagnosis of T1D with at least 12 months duration prior to baseline assessment, currently receiving insulin therapy and access to cellular technology. Additionally, minors under 18 years old require parental or guardian consent while those above 18 can provide their own permission."
Is Libre Pro a risk-free option for patients?
"Through our analysis, Libre Pro has achieved a safety rating of 3 as it is in its final stage of clinical trials and has already been approved."
How many participants are currently enrolled in this experiment?
"Affirmative, the clinical trial is presently accepting patients. According to records posted on clinicialtrials.gov, 180 people must be recruited from a solitary site for this study which was first published on August 15th 2022 and last updated September 16th 2022."
Share this study with friends
Copy Link
Messenger